AR082205A1 - Conjugados de anticuerpos multifuncionales - Google Patents

Conjugados de anticuerpos multifuncionales

Info

Publication number
AR082205A1
AR082205A1 ARP110102486A ARP110102486A AR082205A1 AR 082205 A1 AR082205 A1 AR 082205A1 AR P110102486 A ARP110102486 A AR P110102486A AR P110102486 A ARP110102486 A AR P110102486A AR 082205 A1 AR082205 A1 AR 082205A1
Authority
AR
Argentina
Prior art keywords
antibody
conjugates
group
covalently connected
multifunctional antibodies
Prior art date
Application number
ARP110102486A
Other languages
English (en)
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Publication of AR082205A1 publication Critical patent/AR082205A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente se refiere a Conjugados de Anticuerpos Multifuncionales, que comprenden un anticuerpo o porción de unión a antígeno del mismo, que comprende al menos un fragmento de una región k constante de cadena ligera (CLk), que comprende K188 de acuerdo con la numeración Kabat; un engarce que comprende la fórmulas X-Y-Z, en la que Z es un grupo que está conectado covalentemente al anticuerpo a través de la cadena lateral de K188, Y es una cadena de conexión biológicamente compatible lineal o ramificada, y X es un grupo conectado covalentemente a al menos un Resto Efector. Se proporciona además compuestos y composiciones de MAC específicos.
ARP110102486A 2010-07-12 2011-07-11 Conjugados de anticuerpos multifuncionales AR082205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36350710P 2010-07-12 2010-07-12

Publications (1)

Publication Number Publication Date
AR082205A1 true AR082205A1 (es) 2012-11-21

Family

ID=44630490

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102486A AR082205A1 (es) 2010-07-12 2011-07-11 Conjugados de anticuerpos multifuncionales

Country Status (18)

Country Link
US (1) US8741291B2 (es)
EP (1) EP2593142B8 (es)
JP (2) JP5913307B2 (es)
KR (1) KR20130050966A (es)
CN (1) CN103096933A (es)
AR (1) AR082205A1 (es)
AU (1) AU2011277999A1 (es)
BR (1) BR112013000951A2 (es)
CA (1) CA2804185C (es)
CO (1) CO6670522A2 (es)
ES (1) ES2704223T3 (es)
MX (1) MX2013000491A (es)
PE (1) PE20130643A1 (es)
RU (1) RU2012157167A (es)
SG (1) SG186451A1 (es)
TW (1) TWI432213B (es)
WO (1) WO2012007896A1 (es)
ZA (1) ZA201300161B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG190082A1 (en) * 2010-11-05 2013-06-28 Covx Technologies Ireland Ltd Anti-diabetic compounds
SG195172A1 (en) * 2011-06-21 2013-12-30 Immunogen Inc Novel maytansinoid derivatives with peptide linker and conjugates thereof
US8828401B2 (en) 2011-11-17 2014-09-09 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
EP3447071A1 (en) 2012-01-09 2019-02-27 Pfizer Healthcare Ireland Mutant antibodies and conjugation thereof
KR102584005B1 (ko) 2012-10-11 2023-09-27 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
JP6272230B2 (ja) 2012-10-19 2018-01-31 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート
WO2014072888A1 (en) 2012-11-07 2014-05-15 Pfizer Inc. Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates
TW201726746A (zh) 2012-11-07 2017-08-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
EP3489258A1 (en) 2012-11-08 2019-05-29 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015057063A1 (en) * 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
CN105829543B (zh) * 2013-10-14 2021-06-01 西纳福克斯股份有限公司 糖基改造的抗体、抗体-缀合物及其制备方法
RU2743077C2 (ru) 2013-12-25 2021-02-15 Дайити Санкио Компани, Лимитед Конъюгат анти-trop2 антитело-лекарственное средство
CN105829346B (zh) * 2014-01-31 2019-08-23 第一三共株式会社 抗her2抗体－药物偶联物
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
ES2859648T3 (es) 2014-04-10 2021-10-04 Daiichi Sankyo Co Ltd Conjugado anticuerpo-fármaco anti-HER3
SG11201703574VA (en) 2014-11-07 2017-05-30 Eleven Biotherapeutics Inc Improved il-6 antibodies
CN107847588B (zh) * 2015-05-20 2021-12-28 免疫功坊股份有限公司 具有靶向部分及效应部分的分子构建体及其应用
BR112017027252A2 (pt) * 2015-06-19 2018-08-28 Eisai R&D Management Co., Ltd. imunoglobulinas conjugadas a cys80
ES2938186T3 (es) 2015-06-29 2023-04-05 Daiichi Sankyo Co Ltd Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco
CA2996652A1 (en) * 2015-09-01 2017-03-09 Immunwork Inc. Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
JP6990650B2 (ja) * 2015-09-17 2022-03-04 ザ スクリプス リサーチ インスティテュート 二重可変ドメインイムノコンジュゲートおよびその用途
JP2018537076A (ja) * 2015-10-23 2018-12-20 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． プログラム可能な普遍的細胞受容体およびその使用法
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
JP2019518017A (ja) 2016-02-09 2019-06-27 アレクサンダー・クランツ トレースレス親和性標識を使用したタンパク質の部位選択的官能化
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY MEDICINAL CONJUGATE
WO2018138591A1 (en) 2017-01-24 2018-08-02 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
WO2019044947A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
CN117838881A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
JP2021502418A (ja) * 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
EP4257611A3 (en) 2018-05-18 2024-03-06 Glycotope GmbH Anti-muc1 antibody
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
KR20220045047A (ko) * 2019-08-19 2022-04-12 션양 파마슈티컬 유니버시티 항체 변이체 및 이의 적용
WO2021046347A1 (en) 2019-09-04 2021-03-11 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
CN118201640A (zh) * 2021-11-01 2024-06-14 达因疗法公司 用于治疗肌养蛋白病的肌肉靶向复合物
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2023201324A1 (en) * 2022-04-15 2023-10-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
CA2389250C (en) 1999-10-08 2010-07-20 The Scripps Research Institute Antibody catalysis of enantio- and diastereo-selective aldol reactions
DZ3494A1 (fr) 2001-01-05 2002-07-11 Pfizer Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline
WO2003059251A2 (en) 2001-10-22 2003-07-24 The Scripps Research Institute Antibody targeting compounds
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
JP4638870B2 (ja) 2003-08-13 2011-02-23 ファイザー・プロダクツ・インク 修飾ヒトｉｇｆ−１ｒ抗体
EP2292248A3 (en) 2005-03-03 2011-06-29 CovX Technologies Ireland Limited Anti-angiogenic compounds
NZ576751A (en) 2006-11-10 2011-10-28 Covx Technologies Ireland Ltd Anti-angiogenic compounds
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
WO2009032145A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
WO2009088805A2 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies

Also Published As

Publication number Publication date
TW201216986A (en) 2012-05-01
EP2593142A1 (en) 2013-05-22
ES2704223T3 (es) 2019-03-15
US8741291B2 (en) 2014-06-03
PE20130643A1 (es) 2013-06-07
US20120201809A1 (en) 2012-08-09
CA2804185A1 (en) 2012-01-19
JP2016094455A (ja) 2016-05-26
AU2011277999A1 (en) 2013-01-10
JP6339995B2 (ja) 2018-06-06
WO2012007896A1 (en) 2012-01-19
BR112013000951A2 (pt) 2016-05-17
EP2593142B1 (en) 2018-10-10
MX2013000491A (es) 2013-02-26
SG186451A1 (en) 2013-01-30
CO6670522A2 (es) 2013-05-15
KR20130050966A (ko) 2013-05-16
JP2013534535A (ja) 2013-09-05
ZA201300161B (en) 2013-09-25
CA2804185C (en) 2017-03-21
JP5913307B2 (ja) 2016-04-27
CN103096933A (zh) 2013-05-08
TWI432213B (zh) 2014-04-01
RU2012157167A (ru) 2014-08-20
EP2593142B8 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
AR082205A1 (es) Conjugados de anticuerpos multifuncionales
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
CY1115639T1 (el) Διειδικα αγωνιστικα αντισωματα υποδοχεα θανατου
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
CY1115932T1 (el) Σκευασμα αντισωματος
BR112018014986A2 (pt) composição farmacêutica compreendendo construtos de anticorpo biespecífico
GT200500298A (es) Formulaciones de anticuerpos
CR10563A (es) Anticuerpos monoclonales ant-il-6 y usos de los mismos
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CY1121673T1 (el) Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficile
CR20110400A (es) Proteinas de enlace al receptor cgrp humano
CR20110566A (es) Inmunoconjugados de antimesotelina y usos de los mismos
GT201200046A (es) Conjugados de dímeros de pirrolo[1,4] benzodiazepina como agentes anticancerosos
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
CO6450689A2 (es) Variantes de unión a anti-albúmina de suero mejoradas
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
UY38207A (es) Anticuerpos anti-esclerostina
PE20150222A1 (es) Anticuerpos multiespecificos
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
AR088920A1 (es) Purificacion de anticuerpos anti-c-met

Legal Events

Date Code Title Description
FA Abandonment or withdrawal